相关临床试验
7
2 进行中
药物批准
25
批准总数
监管机构
2
监管机构数
成立时间
N/A
进行中（未招募）
1
14.3%
已完成
4
57.1%
尚未招募
1
14.3%
招募中
1
14.3%
- Chandigarh University's biotechnology and pharmaceutical sciences programs placed 178 students and secured 261 industry internships over three years with companies including Sun Pharma, GSK, and Serum Institute of India. - The University Institute of Biotechnology contributed 118 placements, with MSc Biotechnology recording the highest selections at 59 students and the top salary package reaching ₹8 lakh annually. - The University Institute of Pharmaceutical Sciences achieved 60 placements, with a Pharm.D student securing the highest package of ₹9.6 LPA at Karuna Cancer Hospital. - Students have also achieved international academic success, published over 40 research papers, and founded startups including Nutripanda Life Care LLP and Nubody&CO.
- Gates MRI and Serum Institute of India reach agreement to manufacture the M72/AS01E TB vaccine candidate, pending Phase 3 trial outcomes. - The vaccine could be the first new TB vaccine in over a century and the first ever specifically for adolescents and adults. - Phase 3 trial enrolled 20,000 participants across 54 sites in five countries, with results expected to determine regulatory pathway. - WHO modeling suggests a vaccine with M72's Phase 2b efficacy profile could prevent 76 million TB cases and save 8.5 million lives over 25 years.
- The global vaccine sales market is projected to reach US$141.40 billion by 2036, driven by next-generation platforms including mRNA and viral vector technologies. - U.S. tariff policies and cross-border supply chain vulnerabilities are reshaping competitive strategy, with manufacturers localizing production and diversifying suppliers to manage cost pressures. - Competition is increasingly defined by platform capabilities, regulatory credentials, manufacturing scale, and access to government and multilateral procurement contracts. - The report profiles 21 leading vaccine companies including GSK, Pfizer, Sanofi, Moderna, Merck, BioNTech, AstraZeneca, and Serum Institute of India, with forecasts across 26 national markets.
- The Drugs for Neglected Diseases initiative (DNDi) and Serum Institute of India (SII) have signed a licensing agreement to advance a monoclonal antibody dengue treatment into Phase III trials. - The 1,000-participant study is expected to begin in Q1 2027 across Malaysia, Thailand, and Brazil, with SII supplying the investigational drug. - The antibody, formerly known as VIS513, targets all four dengue virus serotypes and has shown promising safety and efficacy in earlier trials. - The trial is funded by the European Commission's DG HERA and the French Development Agency, with DG HERA committing €20 million to advance two dengue medicines.
- Intravacc and Primrose Bio have renewed their strategic partnership to enhance conjugate vaccine development and manufacturing capabilities for third-party clients. - The collaboration combines Intravacc's expertise in vaccine conjugation and GMP production with Primrose Bio's PeliCRM197® carrier protein technology. - The partnership creates a seamless full-service solution spanning from early-stage development through clinical manufacturing for vaccine developers. - PeliCRM197® represents the only CRM197 carrier protein used in commercial vaccines that is available for purchase, offered in research and GMP grades.
- The WHO has prioritized three experimental treatments—MBP134, maftivimab, and remdesivir—for the Bundibugyo strain of Ebola, with clinical trials set to begin in the DRC. - Africa CDC has issued an urgent appeal for $18 million to support therapeutic trials, warning that funding shortfalls could delay life-saving research. - Among vaccines, the rVSV Bundibugyo candidate from IAVI is considered most promising but remains 7–9 months from trial readiness, while ChAdOx1 Bundibugyo could be available in 2–3 months. - No approved vaccines or therapies currently exist specifically for Bundibugyo virus disease, underscoring the critical unmet medical need.
- The Serum Institute of India will manufacture up to 100,000 doses of Oxford's investigational ChAdOx1 RVF vaccine candidate, creating the largest-ever reserve for Rift Valley fever vaccine testing. - The collaboration comes as a deadly outbreak in West Africa has reported over 610 confirmed cases and 47 deaths in Senegal and Mauritania according to WHO data. - CEPI is providing up to $3.5 million to support the development and manufacturing, with 10,000 doses designated for potential clinical trials in outbreak-affected regions. - The ChAdOx1 RVF vaccine has completed Phase I trials showing safety and immune response generation, with a Phase II trial currently underway in Kenya.
- The University of Oxford has initiated the world's first Phase II clinical trial of a Nipah virus vaccine candidate in Bangladesh, marking a critical milestone in pandemic preparedness efforts. - The ChAdOx1 NipahB vaccine trial will enroll 306 healthy participants aged 18-55 to assess safety and immune response in a region experiencing regular Nipah outbreaks. - Nipah virus poses a severe public health threat with a case fatality rate of up to 75% and is recognized by WHO as a priority pathogen with pandemic potential. - The vaccine uses the same viral vector platform as the Oxford/AstraZeneca COVID-19 vaccine and has received PRIME designation from the European Medicines Agency to expedite development.
- India has launched its first indigenous CRISPR-based gene therapy called "BIRSA 101" for sickle cell disease, developed by CSIR-IGIB and transferred to Serum Institute of India for clinical trials. - The therapy aims to reduce treatment costs from approximately Rs 26 crore (USD 3 million) to around Rs 50 lakh, making it accessible to India's tribal populations who are disproportionately affected. - Clinical trials have begun with 150 potential participants from Madhya Pradesh, Chhattisgarh, and Jharkhand, with the first phase involving three participants after regulatory approvals. - This breakthrough positions India among global leaders in gene therapy and supports Prime Minister Modi's vision of a Sickle Cell-Free India by 2047.
- The Coalition for Epidemic Preparedness Innovations (CEPI), University of Oxford, and Serum Institute of India announced a collaboration to create the world's largest investigational reserve of Nipah virus vaccine doses. - CEPI will provide up to $7.3 million in funding to support manufacturing of 100,000 doses of the ChAdOx1 NipahB vaccine candidate for Phase II trials and emergency outbreak response. - The initiative addresses a critical unmet medical need, as Nipah virus has a fatality rate of up to 75 percent with no currently approved countermeasures. - The vaccine uses the same viral vector platform as the Oxford-AstraZeneca COVID-19 vaccine, leveraging Serum Institute's proven manufacturing capabilities from producing over 2 billion COVID-19 vaccine doses.
